Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06580314

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

Sponsor: NRG Oncology

Conditions FIGO Stage III Ovarian Cancer 2014 FIGO Stage IV Ovarian Cancer 2014 Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube High Grade Serous Adenocarcinoma Ovarian Carcinoma Ovarian High Grade Endometrioid Adenocarcinoma Ovarian High Grade Serous Adenocarcinoma Primary Peritoneal Endometrioid Adenocarcinoma Primary Peritoneal High Grade Serous Adenocarcinoma

Interventions Bevacizumab Biospecimen Collection Computed Tomography Magnetic Resonance Imaging Olaparib

Updated 5 times since 2024 Last updated: Jan 12, 2026 Started: Mar 12, 2025 Primary completion: Dec 31, 2034 Completion: Dec 31, 2034

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates FIGO Stage III Ovarian Cancer 2014 and FIGO Stage IV Ovarian Cancer 2014 and is currently actively recruiting participants. NRG Oncology leads this study, which shows 5 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Recruiting PHASE3
Nov 2025 — Feb 2026 [monthly]

Recruiting PHASE3
Sep 2025 — Nov 2025 [monthly]

Recruiting PHASE3
Jun 2025 — Sep 2025 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2024 — Jun 2025 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NRG Oncology
National Cancer Institute (NCI)

Data source: NRG Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United States , Aitkin, United States , Akashi, Japan , Albuquerque, United States , Allentown, United States , Alma, United States , Alpena, United States , Alton, United States , Ames, United States , Anaconda, United States and 434 more locations